Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients. Materials and Methods Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected. Results Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis. Conclusion Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.
Abstract
Purpose Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients. Materials and Methods Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected. Results Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis. Conclusion Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.
참고문헌 (21)
- Harake D, "Cardiotoxicity in childhood cancer survivors : strategies for prevention and management", Future Cardiol, 8, pp.647~670 (2012)
- Brewster DH, "Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland : a population based, retrospective cohort study", Br J Cancer, 110, pp.1342~1350 (2014)
- 최형수, "Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors", Journal of Korean Medical Science, 25(9), pp.1336~1342 (2010), 대한의학회
- Barry EV, "Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane", J Clin Oncol, 26, pp.1106~1111 (2008)
- Tebbi CK, "Dexrazoxane-associated risk for acute myeloid leukemia", myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease, 2007, pp.25, 493~500
- Walker DM, "Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009 : analysis of a national cohort of patients in the Pediatric Health Information Systems database", Pediatr Blood Cancer, 60, pp.616~620 (2013)
- Vrooman LM, "The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia : a report from the Dana-Farber Cancer Institute ALL Consortium", Eur J Cancer, 47, pp.1373~1379 (2011)
- Seif AE, "Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients", Pediatr Blood Cancer, 62, pp.704~709 (2015)
- Blanco JG, "Anthracycline-related cardiomyopathy after childhood cancer : role of polymorphisms in carbonyl reductase genes : a report from the Children's Oncology Group", J Clin Oncol, 30, pp.1415~1421 (2012)
- Florescu M, "Chemotherapy-induced cardiotoxicity", Maedica(Buchar), 8, pp.59~67 (2013)
- Kremer LC, "Anthracycline-induced clinical heart failure in a cohort of 607 children : long-term follow-up study", J Clin Oncol, 19, pp.191~196 (2001)
- Lipshultz SE, "Cardiotoxicity after childhood cancer : beginning with the end in mind", J Clin Oncol, 28, pp.1276~1281 (2010)
- Lipshultz SE, "Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia : long-term follow-up of a prospective, randomised, multicentre trial", Lancet Oncol, 11, pp.950~961 (2010)
- Mozdzanowska D, "Radiotherapy and anthracyclines : cardiovascular toxicity", Contemp Oncol(Pozn), 19, pp.93~97 (2015)
- Swain SM, "Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three trials", Cancer, 97, pp.2869~2879 (2003)
- Vega-Stromberg T, "Chemotherapy-induced secondary malignancies", J Infus Nurs, 26, pp.353~361 (2003)
- Hawkins MM, "Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer", BMJ, 304, pp.951~958 (1992)
- Haddy N, "Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood", Eur J Cancer, 42, pp.2757~2764 (2006)
- Friedman DL, "Subsequent neoplasms in 5-year survivors of childhood cancer : the Childhood Cancer Survivor Study", J Natl Cancer Inst, 102, pp.1083~1095 (2010)
- Choi DK, "Secondary malignancies in pediatric cancer survivors : perspectives and review of the literature", Int J Cancer, 135, pp.1764~1773 (2014)
- Bhuller KS, "Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma : report of the Childhood", Adolescent, Br J Haematol, pp.2016, 172[DOI]